NCT04145349

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 12 Months – 29 Years
• Healthy volunteers: Not accepted

Summary

This study is being conducted to test the safety and efficacy of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory desmoplastic small round cell tumor (DSRCT) in children and young adults. This trial is part of the CAMPFIRE master protocol (NCT05999994) which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond.

Conditions

• Desmoplastic Small Round Cell Tumor

Interventions

Type	Name	Description
DRUG	Ramucirumab	Administered IV
DRUG	Cyclophosphamide	Administered orally
DRUG	Vinorelbine	Administered IV

Timeline

• Start date: 2020-01-22
• Primary completion: 2024-06-14
• Completion: 2026-10-01
• First posted: 2019-10-30
• Last updated: 2025-12-08
• Results posted: 2025-07-20

Locations

22 sites across 7 countries: United States, Australia, Germany, Italy, Japan, Spain, United Kingdom

Regulatory

• FDA-regulated drug study